Drug Trial Radar · NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Sep 30, 2021
Primary completion
Jun 14, 2023
Study completion Mar 2, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Aug 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, B-cell Marginal Zone
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- B-cell Lymphoma
- Waldenstrom Macroglobulinemia
- Lymphoma, Mantle-Cell
Interventions
LOXO-338Drug
Oral
PirtobrutinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338Time frame: Cycle 1 (28 Days)
- Part 1 - To determine the effect of LOXO-338 on response ratesTime frame: Estimated up to 2 years
- Part 2 - To determine the safety and tolerability of LOXO-338 when given in combination with pirtobrutinibTime frame: Cycle 2 (28 Days)
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
University of California San Francisco, Medical Center at Paranassus
San Francisco, California
Mayo Clinic in Florida
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Emory University
Atlanta, Georgia
Indiana Blood & Marrow Transplantation (IBMT)
Indianapolis, Indiana
University of Kansas Medical Center
Westwood, Kansas
Tufts Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
Swedish Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
CHRU de Montpellier-Hopital St Eloi
Montpellier, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
Nantes, France
Institut Curie
Paris, France
Centre hospitalier universitaire de Haut Leveque
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Cedex, France
L'Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, Cedex 9, France
IRCCS - AOU di Bologna
Bologna, Italy
Pratia MCM Krakow
Krakow, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, Poland
Centrum Medyczne Pratia Poznan
Skorzewo, Poznan, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.